Abstract: Amorphous solid dispersions of nilotinib fumarate or nilotinib tartrate are provided, as well as pharmaceutical compositions thereof, wherein the compositions exhibit enhanced bioavailability in the fasted state. Preferably, the compositions may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Cmax, AUC0-t and/or AUC0-infinity) of nilotinib, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.

Abstract: The present invention relates to an improved process for the preparation of Valacyclovir or pharmaceutically acceptable salts thereof, which comprises reaction of amine-protected Valacyclovir or its salt with deprotecting agent in a continuous flow reactor.

Abstract: The present invention provides a preservative free ophthalmic formulation. In particular, the ophthalmic formulations of the invention are aqueous formulations comprising nanoemulsion of oil. The present invention also provides a method for treating an eye disorder. In one particular embodiment, the invention provides methods for treating dry eye syndrome using an preservative free formulation comprising a nanoemulsion of oil and alpha 2 adrenergic agonist, pharmaceutically acceptable salt thereof or a mixture thereof. In particular, the alpha 2 adrenergic agonist of the invention has a higher alpha 2A agonist activity compared to alpha 2B agonist activity. This invention also provides a preservative free ophthalmic composition comprising a nanoemulsion of oil, a therapeutically effective amount of an alpha 2 adrenergic agonist, a pharmaceutically acceptable salt thereof or a combination thereof as an active ingredient for treating a dry eye syndrome.

Abstract: Amorphous solid dispersions of nilotinib fumarate or nilotinib tartrate are provided, as well as pharmaceutical compositions thereof, wherein the compositions exhibit enhanced bioavailability in the fasted state. Preferably, the compositions may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Cmax, AUC0-t and/or AUC0-infinity) of nilotinib, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.

Abstract: Solid dispersions of lurasidone or a pharmaceutically acceptable salt thereof are described, as well as pharmaceutical formulations thereof, and methods for making such formulations. Preferably, the solid dispersions are prepared by hot-melt extrusion or spray-drying, and comprise lurasidone with a pharmaceutically acceptable carrier (e.g., hydroxypropyl methyl cellulose acetate succinate (HPMC-AS), polyvinyl pyrrolidine vinyl acetate (PVP/VA) copolymer, hydroxypropyl methylcellulose phthalate (HPMCP), or mixtures thereof). The pharmaceutical composition may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Tmax, Cmax, AUC0-t and/or AUC0-infinity) of lurasidone, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.

Abstract: Solid dispersions of lurasidone or a pharmaceutically acceptable salt thereof are described, as well as pharmaceutical formulations thereof, and methods for making such formulations. Preferably, the solid dispersions are prepared by hot-melt extrusion or spray-drying, and comprise lurasidone with a pharmaceutically acceptable carrier (e.g., hydroxypropyl methyl cellulose acetate succinate (HPMC-AS), polyvinyl pyrrolidine vinyl acetate (PVP/VA) copolymer, hydroxypropyl methylcellulose phthalate (HPMCP), or mixtures thereof). The pharmaceutical composition may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Tmax, Cmax, AUC0-t and/or AUC0-infinity) of lurasidone, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.

Abstract: A device is disclosed. The device includes a read-only memory (ROM), a random key generator, a lifecycle controller, an access port and a processor. The processor is configured, based on a lifecycle status, to cause the random key generator to generate a secret key and store the secret key in the ROM. The lifecycle controller is configured to disable an external access via the access port until the secret key is stored in the ROM.

Abstract: A system for securing a secret word during a read of the secret word from a read-only memory (ROM) is disclosed. The system includes a memory controller coupled to the ROM and a random number generator coupled to the memory controller. The random number generator is configured to generate a random number. The system further includes a number shuffler coupled to the random number generator and the memory controller. The number shuffler is configured to generate a bit read order based on the random number and the memory controller is configured to read bits of the secret word from the ROM according to the bit read order.

Abstract: Coolers for dispensing products, such as beverages, having multiple doors for accessing a single product compartment. A cooler may include a housing defining a product compartment; a top door coupled to a top surface of the housing at a hinge, the top door comprising a curved transparent panel; a vertical door coupled to a vertical front surface of the housing; a collapsible shelf disposed in the product compartment that is configured to move between an extended position and a retracted position; and a lower shelf disposed below the collapsible shelf in the product compartment. A product disposed on the collapsible shelf may be accessible through the top door when the collapsible shelf is in the extended position and a product disposed on the lower shelf may be accessible through the top door when the collapsible shelf is in the retracted position.

Abstract: The present invention provides a composition comprising two or more of the following pharmaceutically active compounds: (i) an alpha 2 adrenergic agonist; (ii) a corticosteroid; (iii) a lymphocyte function-associated antigen antagonist; (iv) a non-steroidal anti-inflammatory drug (NSAID); (v) a sodium channel blocker; and (vi) an antibiotic, provided at least one of the pharmaceutically active compound is selected from the group consisting of (i) alpha 2 adrenergic agonist and (ii) corticosteroid.

Abstract: In accordance with an embodiment, described herein is a system and method for optimizing cloud infrastructure through client request classification in a cloud computing environment. The cloud infrastructure can include one or more high-compute infrastructure instances, and one or more standard-compute infrastructure instances. Each request received at a load balancer can be checked against a request classification cache, to determine whether the request has been classified, and if it has been classified, whether the request can be routed to a high-compute infrastructure instance or a standard-compute infrastructure instance based on a classification of the request. An unclassified request can be classified based on a plurality of request parameters, and threshold values derived from the cloud infrastructure; and can be stored in the request classification cache. Classified requests in the classification cache can be provided to a cloud vendor for use in optimizing the cloud infrastructure.

Abstract: A system and method for analyzing risk factors to enhance the quality of program code have been disclosed. The risks are identified and evaluated, post which test cases are defined for each of the identified risk factors. Further, the defect density, code complexity and change rate corresponding to each of the test cases is determined. Risk profiles are created for each of the test cases. The risk profiles are categorized based on defect density, complexity of the code and change rate. The test cases are evaluated depending upon the risk posed by new scripts added to the program code. The scripts need to be executed for satisfying a necessary and sufficient condition are decided based on the correlation between program code files, activities on those files, defects corresponding to those files and test cases used to test those defects.

Abstract: A messaging server with a future message storage space for future messages, each being a sender created message not yet delivered to a recipient that has an associated sender specified message delivery time. Recipient specific delivery block details are specified for a set of delivery blocks for future messages. The future messages are received processed and stored. Until the respective sender specified message delivery time a respective one of the set of senders is able to retract and edit a corresponding one of the future messages. Future messages are delivered at the delivery time consistent with the delivery blocks. After delivery the sender is unable to retract and edit a corresponding delivered message. Future messages do not alert a recipient of arrival until the sender established delivery time, which minimizes cognitive distractions and provides the sender with notice for anticipating a time of response, without overly distracting the recipient.

Abstract: A system and method to record and trace data exchanges between cooperating hardware unit operations and software unit operations, providing an efficient mechanism to trace back to a root cause point from an observed failure point in a series of executed instructions performed within a data processing system. A data debug memory records information pertaining to each system memory access performed by instructions executed by the hardware and software units into separate memory information blocks. Linked relationships are created between certain ones of the memory information blocks to represent data dependencies that occurred between the instructions. These linked relationships may then be utilized to generate lists that map the various data dependencies between the executed instructions.

Abstract: Provided herein is a composition and a method for treating nucleic acid-related eye disease.

Abstract: Systems and method for idle loop detection and control are disclosed. A processor operates in operating modes including an active mode and a disabled mode, and an interconnect bus is coupled between the processor and one or more additional electronic circuits. Logic within the processor is coupled to snoop the interconnect bus, and the logic is programmed to detect a new idle loop based upon repeated instructions on the interconnect bus and to place the processor in the disabled mode based upon execution of the new idle loop, which represents a previously unknown idle loop for the processor. Further, the logic can be programmed to store state data for the processor when the new idle loop is detected, and the logic can also be programmed to place the processor in the active mode based upon detection of a wakeup event for the new idle loop on the interconnect bus.

Abstract: A containerized architecture to secure and manage Internet-connected devices, such as “Internet of Things” devices, is disclosed. In various embodiments, one or more containerized applications are run, e.g., on an Internet of Things gateway, subject to management by the management server. At least one of the containerized applications is a management agent configured to participate, subject to control of the management server, in management of one or more other of said containerized applications.

Abstract: Provided herein is a composition and a method for treating nucleic acid-related eye disease.

Abstract: Various embodiments relate to a circuit, including: a first secure circuit configured to receive an input and to produce a first output; a first delay circuit configured to receive the first output and to produce a first delayed output delayed by a time N; a second delay circuit configured to receive the input and to produce a delayed input delayed by a time N; a second secure circuit configured to receive the delayed input and to produce a second delayed output; and a comparator configured to compare the first delayed output to the second delayed output and to produce a result, wherein the result is one of the first delayed output or second delayed output when the first delayed output matches the second delayed output and the result is an error value when the first delayed output does not match the second delayed output.

Abstract: The various embodiments herein disclose a system and method for generating a delta code coverage information. The system for generating delta code coverage information comprises, a source control module configured for storing a plurality of software program code files to be processed and a plurality of code coverage data corresponding to the plurality of software program code files, a processor configured to generate a delta code coverage data for analysis for each of the plurality of software program code files on a line level or at a branch level by performing a time based delta code coverage process and a path based delta code coverage process.